Semaglutide reduces heart attack risk by 20%

theguardian.com

A study presented at the European Congress of Obesity revealed that the weight loss injection semaglutide reduced the risk of heart attacks by 20%. The medication could benefit millions of adults in the UK, regardless of starting weight. Semaglutide is considered a gamechanger in cardiovascular health and could be widely prescribed. Another study showed participants lost 10.2% body weight with semaglutide. Retatrutide, a new slimming jab, led to 24% weight loss in a trial.


With a significance score of 4.7, this news ranks in the top 2.3% of today's 28684 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: